Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TNYA Tenaya Therapeutics Inc

Market Closed 03-28 16:00:00 EDT

0.6424

-0.0494

-7.14%

盘后0.6400

-0.0024-0.37%

19:50 EDT

High0.6900	Low0.6390	Vol1.60M
Open0.6900	D1 Closing0.6918	Amplitude7.37%
Mkt Cap104.71M	Tradable Cap68.09M	Total Shares163.00M
T/O1.05M	T/O Rate1.51%	Tradable Shares106.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"TNYA","market":"US","secType":"STK","nameCN":"Tenaya Therapeutics Inc","latestPrice":0.6424,"timestamp":1743192000000,"preClose":0.6918,"halted":0,"volume":1601005,"hourTrading":{"tag":"盘后","latestPrice":0.64,"preClose":0.6424,"latestTime":"19:50 EDT","volume":59087,"amount":38131.426,"timestamp":1743205829765},"delay":0,"floatShares":106000000,"shares":163000000,"eps":-1.310136,"marketStatus":"Market Closed","change":-0.0494,"latestTime":"03-28 16:00:00 EDT","open":0.69,"high":0.69,"low":0.639,"amount":1047363.542257,"amplitude":0.073721,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.310136,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":0.6918,"preHourTrading":{"tag":"盘前","latestPrice":0.6825,"preClose":0.6918,"latestTime":"09:28 EDT","volume":95538,"amount":65906.354287,"timestamp":1743168526286},"postHourTrading":{"tag":"盘后","latestPrice":0.64,"preClose":0.6424,"latestTime":"19:50 EDT","volume":59087,"amount":38131.426,"timestamp":1743205829765},"volumeRatio":0.6672468904224895,"impliedVol":1.8045,"impliedVolPercentile":0.548},"requestUrl":"/m/hq/s/TNYA","defaultTab":"news","newsList":[{"id":"2523680413","title":"BRIEF-Tenaya Therapeutics Inc - On Mar 27, Co Approves Restructuring Plan - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2523680413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523680413?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:13","pubTimestamp":1743192786,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics Inc - On Mar 27, Co Approves Restructuring Plan - SEC FilingMarch 28  - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS INC - ON MAR 27, CO APPROVES RESTRUCTURING PLAN - SEC FILINGTENAYA THERAPEUTICS INC - RESTRUCTURING PLAN TO REDUCE CASH EXPENSES - SEC FILINGTENAYA THERAPEUTICS INC - RESTRUCTURING PLAN TO EXTEND CASH RUNWAY INTO H2 2026 - SEC FILINGTENAYA THERAPEUTICS INC - TO REDUCE WORKFORCE UNDER RESTRUCTURING PLAN - SEC FILINGTENAYA THERAPEUTICS INC - TO INCUR $1.6 MILLION-$2.7 MILLION IN RESTRUCTURING CHARGES - SEC FILINGTENAYA THERAPEUTICS INC - EXPECTS TO RECOGNIZE CHARGES BY Q3 2025 - SEC FILINGSource text: [ID:n0001193125-25-067071]Further company coverage: TNYA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB1AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","BK4139","BK4539"],"gpt_icon":0},{"id":"2523680170","title":"Tenaya Therapeutics Inc - on Mar 27, Co Approves Restructuring Plan - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2523680170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523680170?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:10","pubTimestamp":1743192603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB1AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4539","BK4139"],"gpt_icon":0},{"id":"2522501614","title":"Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522501614","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522501614?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 22:43","pubTimestamp":1743173027,"startTime":"0","endTime":"0","summary":"We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Tenaya Therapeutics, Inc.  stands against other cheapest stocks insiders are buying in March.After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, while the NASDAQ Composite rose 0.2%. Monday’s enthusiasm came from hopes of looser U.S. tariffs.Investors mostly ignored the March consumer confidence data released on Tuesday, which showed a sharp decline in U.S. consumers’ short-term outlook on income, business, and job conditions, reports CNBC.“Sentiment continues to wane among investors, consumers and businesses as economic concerns and economic policy uncertainty takes its toll,” said Bret Kenwell, U.S. investment analyst at eToro. “Until there’s more certainty on the tariff and macro front, sentiment and confidence remain vulnerable.”What are some of the cheapest stocks insiders have been buying this month so f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tenaya-therapeutics-inc-tnya-cheapest-144347180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4588","USAW.SI","TNYA","NVIW.SI","NQmain","QLD","HCM","TSYW.SI","BK4007",".IXIC","BK4585","MNQmain","SQQQ","PSQ","BK4531","USJW.SI","TQQQ","BK4139","QID"],"gpt_icon":1},{"id":"2522523886","title":"Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2522523886","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522523886?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:27","pubTimestamp":1742916474,"startTime":"0","endTime":"0","summary":"We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Tenaya Therapeutics, Inc.  stands against other stocks that are receiving the most insider investment in March.“The economy is strong overall and has made significant progress toward our goals over the past two years,” Federal Reserve Chair Jerome Powell said during a press conference Wednesday following the decision announcement. “Labor market conditions are solid, and inflation has moved closer to our 2% longer-run goal, though it remains somewhat elevated.”The Fed announced on Wednesday that it would maintain the federal funds rate at its current range of 4.25% to 4.5%. It is also keeping its outlook at two rate cuts for the remainder of this year, writes CNBC.However, the Fed also announced that “uncertainty around the economic outlook has increased.”However, insider selling doesn’t always signal a lack of faith—it may be due to personal finan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tenaya-therapeutics-inc-tnya-among-152754384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","US12M.BOND","US2Y.BOND","US6M.BOND","US3Y.BOND","US7Y.BOND","US30Y.BOND","BK4539","PSQ","QID","TSYW.SI","TQQQ","US5Y.BOND","SQQQ","USAW.SI","US10Y.BOND","BK4139","NQmain","USJW.SI",".IXIC","MNQmain","TNYA","QLD"],"gpt_icon":1},{"id":"2522765008","title":"Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function","url":"https://stock-news.laohu8.com/highlight/detail?id=2522765008","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522765008?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:45","pubTimestamp":1742906750,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tenaya-therapeutics-publishes-preclinical-data-124550777.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tenaya-therapeutics-publishes-preclinical-data-124550777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","TNYA","BK4539","BK4139"],"gpt_icon":0},{"id":"2522650023","title":"Promising Developments in Tenaya Therapeutics’ TN-201 Program Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2522650023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522650023?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 18:46","pubTimestamp":1742899572,"startTime":"0","endTime":"0","summary":"Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target of $6...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-tenaya-therapeutics-tn-201-program-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-tenaya-therapeutics-tn-201-program-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA","LENZ"],"gpt_icon":0},{"id":"2521721364","title":"Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2521721364","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521721364?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 21:22","pubTimestamp":1742822571,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics  said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4539","TNYA","BK4139"],"gpt_icon":0},{"id":"2521729839","title":"Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521729839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521729839?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:52","pubTimestamp":1742820727,"startTime":"0","endTime":"0","summary":"Significant control over Tenaya Therapeutics by individual investors implies that the general public has more power to influence management and governance-related decisions. A total of 25 investors have a majority stake in the company with 49% ownership. A look at the shareholders of Tenaya Therapeutics, Inc.  can tell us which group is most powerful. With 49% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most  from their investment into the company.And following last week's 13% decline in share price, individual investors suffered the most losses.Let's delve deeper into each type of owner of Tenaya Therapeutics, beginning with the chart below.Check out our latest analysis for Tenaya Therapeutics. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tenaya-therapeutics-inc-nasdaq-tnya-125207382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","TNYA","NQmain","BK4585","NVIW.SI","PSQ","IE00B64PRP62.GBP","BK4588","QLD","BK4112","TSYW.SI","BK4139","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BKPKM429.USD",".IXIC","USAW.SI","LU2210150020.SGD","IE00BGHQF748.EUR","LU2095319765.USD","MNQmain","TQQQ","NDAQ","QID","SQQQ","USJW.SI"],"gpt_icon":1},{"id":"2521772332","title":"Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2521772332","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521772332?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:30","pubTimestamp":1742819400,"startTime":"0","endTime":"0","summary":"Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients with MYBPC3-associated Hypertrop","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047852/0/en/Tenaya-Therapeutics-Publishes-Preclinical-Data-Demonstrating-TN-201-Enhances-Cardiac-Function-and-Survival-in-MYBPC3-Cardiomyopathy-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","LENZ"],"gpt_icon":0},{"id":"2521510792","title":"BRIEF-Tenaya Therapeutics files for mixed shelf offering of up to $300 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2521510792","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521510792?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 04:16","pubTimestamp":1742588205,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics files for mixed shelf offering of up to $300 mlnMarch 21  - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS INC: FILES FOR MIXED SHELF OFFERING OF UP TO $300 MILLION - SEC FILINGSource text: [ID:n0001193125-25-060227]Further company coverage: TNYA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q41F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2521203251","title":"Tenaya Therapeutics Inc: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2521203251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521203251?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 04:11","pubTimestamp":1742587919,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q41F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","TNYA"],"gpt_icon":0},{"id":"2519548808","title":"Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2519548808","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519548808?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 00:23","pubTimestamp":1741882980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 12:23 ET (16:23 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","LENZ"],"gpt_icon":0},{"id":"2519853379","title":"Promising Clinical Data and Financial Stability Support Buy Rating for Tenaya Therapeutics Despite Price Target Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2519853379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519853379?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 22:36","pubTimestamp":1741876595,"startTime":"0","endTime":"0","summary":"Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) and decreased the price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-data-and-financial-stability-support-buy-rating-for-tenaya-therapeutics-despite-price-target-reduction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-data-and-financial-stability-support-buy-rating-for-tenaya-therapeutics-despite-price-target-reduction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TNYA"],"gpt_icon":0},{"id":"2518871964","title":"Tenaya Therapeutics price target lowered to $5 from $18 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2518871964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518871964?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 18:15","pubTimestamp":1741688125,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $5 from $18 and keeps a Buy rating on the shares following the Q4 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-price-target-lowered-to-5-from-18-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-price-target-lowered-to-5-from-18-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA","LENZ"],"gpt_icon":0},{"id":"2518812087","title":"Promising Clinical Developments and Strategic Advancements Support Buy Rating for Tenaya Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2518812087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518812087?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 06:15","pubTimestamp":1741644935,"startTime":"0","endTime":"0","summary":"William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on March 6. Sami Corwin has given his Buy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-advancements-support-buy-rating-for-tenaya-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-advancements-support-buy-rating-for-tenaya-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TNYA"],"gpt_icon":0},{"id":"2518783987","title":"Tenaya Therapeutics reports Q4 EPS (28c), consensus (31c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518783987","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518783987?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:25","pubTimestamp":1741638336,"startTime":"0","endTime":"0","summary":"As of December 31 cash, cash equivalents and investments in marketable securities were $61.4M compared to $104.6M as of December 31. With the addit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-reports-q4-eps-28c-consensus-31c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-reports-q4-eps-28c-consensus-31c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA","LENZ"],"gpt_icon":0},{"id":"2518200390","title":"BRIEF-Tenaya Therapeutics Q4 Net Income USD -23.836 Million Vs. IBES Estimate USD -27.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2518200390","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518200390?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:05","pubTimestamp":1741637145,"startTime":"0","endTime":"0","summary":"Mar 10  - Tenaya Therapeutics Q4 operating expenses USD 24.652 million.Q4 operating income USD -24.652 million vs. IBES estimate USD -28.2 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nPLXF11EA5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2518831200","title":"Tenaya Therapeutics Q4 Operating Expenses USD 24.652 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2518831200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518831200?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nPLXF11EA5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","TNYA"],"gpt_icon":0},{"id":"2518200858","title":"Tenaya Therapeutics Q4 Net Income USD -23.836 Million VS. Ibes Estimate USD -27.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2518200858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518200858?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nPLXF11EA5:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","TNYA"],"gpt_icon":0},{"id":"2518200551","title":"Tenaya Therapeutics Q4 Operating Income USD -24.652 Million VS. Ibes Estimate USD -28.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2518200551","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518200551?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nPLXF11EA5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tenayatherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":-0.364},{"period":"3month","weight":-0.5717},{"period":"6month","weight":-0.6764},{"period":"1year","weight":-0.8772},{"period":"ytd","weight":-0.5508}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.092404},{"month":2,"riseRate":0.25,"avgChangeRate":0.060915},{"month":3,"riseRate":0.25,"avgChangeRate":-0.136584},{"month":4,"riseRate":0.333333,"avgChangeRate":0.171888},{"month":5,"riseRate":0.333333,"avgChangeRate":0.002884},{"month":6,"riseRate":0,"avgChangeRate":-0.202694},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.066396},{"month":8,"riseRate":0.25,"avgChangeRate":-0.048786},{"month":9,"riseRate":0.25,"avgChangeRate":-0.235148},{"month":10,"riseRate":0.25,"avgChangeRate":-0.03057},{"month":11,"riseRate":0.5,"avgChangeRate":0.16136},{"month":12,"riseRate":0.25,"avgChangeRate":-0.038292}],"exchange":"NASDAQ","name":"Tenaya Therapeutics Inc","nameEN":"Tenaya Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tenaya Therapeutics Inc,TNYA,Tenaya Therapeutics Inc股票,Tenaya Therapeutics Inc股票老虎,Tenaya Therapeutics Inc股票老虎国际,Tenaya Therapeutics Inc行情,Tenaya Therapeutics Inc股票行情,Tenaya Therapeutics Inc股价,Tenaya Therapeutics Inc股市,Tenaya Therapeutics Inc股票价格,Tenaya Therapeutics Inc股票交易,Tenaya Therapeutics Inc股票购买,Tenaya Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction